Tag Archives: biosimilar

Time to switch? Switching from innovator rituximab to biosimilar CT-P10 is safe and efficacious

Rituximab is a monoclonal antibody that targets the CD20 protein that is found mainly on immune cells called B lymphocytes. By removing CD20-positive B lymphocytes from the peripheral blood and bone marrow, rituximab provides effective treatment for

Long-term safety and efficacy of rituximab biosimilar CT-P10 in rheumatoid arthritis

Rituximab is a monoclonal antibody used to treat certain cancers of the blood, as well as immune-mediated diseases such as rheumatoid arthritis. But while rituximab is effective, it is also expensive, which means that not everyone who

Are less expensive “biosimilar” drugs as effective at treating ankylosing spondylitis?

Ankylosing spondylitis (AS) is a type of arthritis caused by inflammation, in which the main symptom is back pain. When a substance called tumour necrosis factor (TNF) is over-active in the body, it causes inflammation and damage

Clinical studies ask: “Are less expensive ‘biosimilar’ drugs as effective and safe as current drugs?”

Several debilitating diseases caused by disorders in a patient’s immune system – often called ‘immune-mediated diseases’ – have become easier to treat in the last two decades following the discovery of drugs called ‘biologics’. Biologics act on

Hope and concern

The ancient way of curing disease was the administration of natural products to the patient. The next step in drug discovery resulted from advances in chemistry. After isolation of natural active ingredients, synthesis in the laboratory of